Premium
Cardiovascular and Renal Responses Produced by the Central Microinjection of Salvinorin A in Ketamine/Xylaxine‐Anesthetized Rats
Author(s) -
Gottlieb Helmut B,
Ji Lisa,
Cunningham JT
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.1015.8
Subject(s) - diuresis , κ opioid receptor , chemistry , pharmacology , agonist , diuretic , medicine , kidney , anesthesia , receptor
One of active ingredients of Salvia divinorum , Salvinorin A (Sal A), has been shown to be a kappa opioid receptor agonist. The activation of central kappa opioid systems markedly affects renal function (water diuresis) in a manner that is different from any clinically used diuretic to date. The cardiovascular and renal effects produced by central administration of Salvinorin A are yet to be determined. Methods Sprague‐Dawley rats were implanted with chronic arterial, venous and bladder cannulas and infused with isotonic saline (55 ml/min, iv) containing ketamine (1 mg/Kg/min) and xylazine (80 mg/Kg/min). After equilibration, urine was collected during two control periods (C, 10‐min ea) and immediately after ICV Salvinorin A (10 nmol or 30 nmol) for 80 min (10‐min ea). Controls received injections of vehicle (DMSO) into the lateral ventricle (n=6). Results ICV injection of Salvinorin A markedly increased V without significantly changing UNaV or blood pressure. Conclusion In anesthetized rats, Salvinorin A selectively affected urine output (diuresis), whereas the activation of central kappa receptors U‐50488H affects both urine flow and UNaV. From these studies, it is apparent that Salvinorin A's effects on renal differ from those elicited by central kappa agonists (endogenous and synthetic). Supported by HL62579 and NIH EARDA grant.